| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Rutgers University researchers solve problems, tackle the unknown, and discover new technologies that are important to the community, the state and globally. Our Office of Technology Commecialization is dedicated to transferring Rutgers patented technologies to the marketplace and to fostering collaborations between the University and industry, creating products and services to benefit society.
The following are just a few examples of the many available technologies for license by Rutgers University. Please conract the Rutgers Office of Technology Commercialization to see our complete catalog.
| Title | Summary | |
|---|---|---|
| PEG Nanocarriers, Nanogels and Synthesis Methods |
|
A novel platform of PEG-only nanocarriers and nanogels has been developed by Rutgers scientists. The nanocarriers range from 100Da-100kDa and are capable of forming stable nanogels and nanogel aggregates in a variety of sizes from 20-30nm up to greater than 1000nm. The carriers and gels have improved solubility over existing technologies and provide for enhanced loading of drug agents. |
| Multifunctional Nanolipoblockers |
|
Rutgers scientists have developed a novel platform of nanosized particles that bind scavenger receptors to inflammatory cells. This technology enables the reduction of risk of clot formation and limits plaque growth or rupture events. These are critically important as they can lead to myocardial infarction (MI) and stroke, particularly for high risk patients with a history of thrombotic events. The particles function by inhibiting foam cell formation via blocking oxidized LDL uptake and delivering drugs that modulate cholesterol efflux. |